| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.888 | 0.005 | 0.938 | Angiogenesis inhibitor | 0.938 0.004 DBMET03578 0.807 0.005 DBMET01001 | DBMET03578 | |
| 0.732 | 0.004 | 0.732 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.688 0.004 DBMET03578 0.14 0.031 DBMET01001 | ||
| 0.715 | 0.004 | 0.715 | Raf kinase inhibitor | 0.674 0.004 DBMET03578 0.141 0.021 DBMET01001 | ||
| 0.673 | 0.003 | 0.673 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.596 0.007 DBMET03578 0.386 0.113 DBMET01001 | ||
| 0.62 | 0.005 | 0.62 | Vascular endothelial growth factor antagonist | 0.603 0.005 DBMET03578 0.097 0.085 DBMET01001 | ||
| 0.591 | 0.005 | 0.591 | Vascular endothelial growth factor 2 antagonist | 0.579 0.005 DBMET03578 | ||
| 0.577 | 0.003 | 0.577 | Raf kinase C inhibitor | 0.447 0.004 DBMET03578 0.217 0.008 DBMET01001 | ||
| 0.531 | 0.004 | 0.531 | Raf kinase B inhibitor | 0.467 0.004 DBMET03578 0.053 0.047 DBMET01001 | ||
| 0.505 | 0.005 | 0.505 | Vascular endothelial growth factor 3 antagonist | 0.327 0.015 DBMET03578 | ||
| 0.498 | 0.005 | 0.498 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.479 0.005 DBMET03578 | ||
| 0.439 | 0.005 | 0.65 | TIE antagonist | 0.65 0.004 DBMET03578 0.073 0.067 DBMET01001 | DBMET03578 | |
| 0.401 | 0.006 | 0.401 | Cytokine production inhibitor | 0.177 0.045 DBMET03578 0.146 0.065 DBMET01001 | ||
| 0.395 | 0.005 | 0.611 | TIE-2 antagonist | 0.611 0.004 DBMET03578 | DBMET03578 | |
| 0.376 | 0.006 | 0.376 | Growth factor agonist | 0.308 0.013 DBMET03578 0.186 0.078 DBMET01001 | ||
| 0.332 | 0.005 | 0.332 | Stem cell growth factor agonist | 0.241 0.006 DBMET03578 | ||
| 0.33 | 0.006 | 0.33 | Granulocyte macrophage colony stimulating factor antagonist | 0.195 0.023 DBMET03578 | ||
| 0.341 | 0.025 | 0.341 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.21 0.069 DBMET03578 | ||
| 0.313 | 0.023 | 0.313 | TRKC antagonist | 0.228 0.056 DBMET03578 | ||
| 0.304 | 0.03 | 0.304 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.141 0.103 DBMET03578 | ||
| 0.281 | 0.008 | 0.281 | Platelet activating factor alpha antagonist | 0.183 0.02 DBMET03578 | ||
| 0.274 | 0.005 | 0.274 | Epoxide hydrolase inhibitor | 0.134 0.014 DBMET03578 0.064 0.063 DBMET01001 | ||
| 0.281 | 0.013 | 0.281 | Sodium channel blocker | |||
| 0.265 | 0.006 | 0.265 | MAP kinase 3 inhibitor | 0.155 0.059 DBMET03578 | ||
| 0.27 | 0.012 | 0.27 | Cyclin-dependent kinase 8 inhibitor | 0.214 0.028 DBMET03578 | ||
| 0.284 | 0.032 | 0.284 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.184 0.089 DBMET03578 | ||
| 0.271 | 0.023 | 0.271 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.243 0.027 DBMET03578 | ||
| 0.259 | 0.014 | 0.259 | Sodium channel (voltage-gated) blocker | |||
| 0.256 | 0.015 | 0.256 | Vascular endothelial growth factor 1 antagonist | 0.161 0.037 DBMET03578 | ||
| 0.264 | 0.024 | 0.264 | Tyrosine-protein kinase receptor antagonist | |||
| 0.234 | 0.007 | 0.234 | Bcr-Abl kinase inhibitor | 0.151 0.017 DBMET03578 | ||
| 0.273 | 0.05 | 0.273 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.183 0.104 DBMET03578 | ||
| 0.269 | 0.047 | 0.269 | EphB2 antagonist | 0.172 0.109 DBMET03578 | ||
| 0.243 | 0.02 | 0.243 | TRKA antagonist | |||
| 0.254 | 0.036 | 0.254 | LIM domain kinase 1 inhibitor | |||
| 0.218 | 0.006 | 0.218 | Purinergic P2 antagonist | 0.147 0.011 DBMET03578 | ||
| 0.239 | 0.033 | 0.239 | RET inhibitor | 0.104 0.093 DBMET03578 | ||
| 0.21 | 0.009 | 0.21 | Hepatocyte growth factor antagonist | 0.209 0.009 DBMET03578 | ||
| 0.201 | 0.008 | 0.201 | Nav1.8 sodium channel blocker | 0.087 0.036 DBMET03578 | ||
| 0.319 | 0.127 | 0.319 | Analgesic | |||
| 0.188 | 0.005 | 0.359 | Phosphorylase inhibitor | 0.069 0.021 DBMET03578 0.359 0.003 DBMET01001 | DBMET01001 | |
| 0.199 | 0.027 | 0.233 | Platelet activating factor antagonist | 0.233 0.019 DBMET03578 | DBMET03578 | |
| 0.179 | 0.016 | 0.179 | Vanilloid antagonist | |||
| 0.188 | 0.029 | 0.188 | TRKB antagonist | 0.102 0.098 DBMET03578 | ||
| 0.171 | 0.017 | 0.172 | AMP-activated protein kinase stimulant | 0.172 0.017 DBMET01001 | DBMET01001 | |
| 0.199 | 0.045 | 0.199 | Polo-like kinase-3 inhibitor | 0.132 0.106 DBMET03578 | ||
| 0.222 | 0.07 | 0.222 | MAP kinase kinase 3 inhibitor | 0.192 0.148 DBMET03578 | ||
| 0.22 | 0.068 | 0.235 | Platelet aggregation inhibitor | 0.235 0.059 DBMET03578 | DBMET03578 | |
| 0.164 | 0.012 | 0.164 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.1 0.028 DBMET03578 | ||
| 0.166 | 0.015 | 0.166 | Platelet growth factor antagonist | 0.089 0.049 DBMET03578 | ||
| 0.162 | 0.017 | 0.199 | MAP kinase 14 inhibitor | 0.199 0.012 DBMET03578 | DBMET03578 | |
| 0.207 | 0.064 | 0.207 | Focal adhesion kinase 2 inhibitor | |||
| 0.208 | 0.066 | 0.208 | Tyrosine kinase inhibitor | 0.138 0.096 DBMET03578 | ||
| 0.172 | 0.031 | 0.172 | Platelet activating factor beta antagonist | 0.113 0.054 DBMET03578 | ||
| 0.246 | 0.107 | 0.246 | Ca(v)3.3 blocker | |||
| 0.287 | 0.149 | 0.307 | MAP kinase kinase 6 inhibitor | 0.307 0.129 DBMET03578 | DBMET03578 | |
| 0.168 | 0.033 | 0.168 | Aurora-C kinase inhibitor | 0.137 0.07 DBMET03578 | ||
| 0.144 | 0.016 | 0.144 | Vanilloid 1 antagonist | 0.073 0.042 DBMET03578 | ||
| 0.167 | 0.04 | 0.167 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.109 0.078 DBMET03578 | ||
| 0.166 | 0.04 | 0.166 | Abl kinase inhibitor | 0.109 0.078 DBMET03578 | ||
| 0.166 | 0.041 | 0.166 | Aurora-B kinase inhibitor | 0.11 0.072 DBMET03578 | ||
| 0.183 | 0.058 | 0.183 | Protein kinase (CK1) gamma 3 inhibitor | |||
| 0.144 | 0.021 | 0.153 | p38 MAP kinase inhibitor | 0.153 0.019 DBMET03578 | DBMET03578 | |
| 0.171 | 0.055 | 0.171 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.128 | 0.015 | 0.128 | Nav1.7 sodium channel blocker | |||
| 0.169 | 0.057 | 0.169 | Protein-tyrosine kinase Lyn inhibitor | |||
| 0.13 | 0.022 | 0.136 | MAP kinase 11 inhibitor | 0.136 0.021 DBMET03578 | DBMET03578 | |
| 0.165 | 0.059 | 0.165 | Protein kinase (CK1) gamma inhibitor | |||
| 0.129 | 0.027 | 0.129 | MAP kinase kinase 1 inhibitor | 0.09 0.07 DBMET03578 | ||
| 0.102 | 0.007 | 0.102 | Stearoyl-CoA desaturase inhibitor | |||
| 0.134 | 0.039 | 0.134 | CDK3/cyclin E inhibitor | 0.118 0.057 DBMET03578 | ||
| 0.111 | 0.019 | 0.111 | Amidase inhibitor | |||
| 0.143 | 0.051 | 0.143 | Sphingosine 1-phosphate receptor 2 antagonist | 0.114 0.113 DBMET03578 | ||
| 0.141 | 0.053 | 0.141 | Protein kinase (CK1) gamma 2 inhibitor | |||
| 0.153 | 0.067 | 0.153 | Growth factor antagonist | 0.118 0.093 DBMET03578 | ||
| 0.18 | 0.095 | 0.18 | MAP kinase kinase 2 inhibitor | |||
| 0.129 | 0.046 | 0.129 | EphA2 antagonist | |||
| 0.146 | 0.064 | 0.146 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | |||
| 0.111 | 0.032 | 0.111 | AXL receptor tyrosine kinase inhibitor | |||
| 0.169 | 0.096 | 0.169 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.126 | 0.055 | 0.126 | Interleukin 8 antagonist | 0.106 0.084 DBMET03578 | ||
| 0.11 | 0.039 | 0.205 | Potassium channel activator | 0.205 0.008 DBMET03578 | DBMET03578 | |
| 0.117 | 0.049 | 0.117 | Interleukin 2 antagonist | |||
| 0.083 | 0.015 | 0.09 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.09 0.012 DBMET03578 | DBMET03578 | |
| 0.079 | 0.014 | 0.079 | Purinergic P2X antagonist | 0.073 0.016 DBMET03578 | ||
| 0.138 | 0.073 | 0.138 | Lck kinase inhibitor | |||
| 0.133 | 0.07 | 0.133 | Nav1.2 sodium channel blocker | |||
| 0.094 | 0.037 | 0.094 | Fibroblast growth factor 3 antagonist | |||
| 0.123 | 0.071 | 0.123 | MAP kinase kinase inhibitor | |||
| 0.092 | 0.04 | 0.092 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | |||
| 0.083 | 0.032 | 0.083 | Fibroblast growth factor 2 antagonist | |||
| 0.1 | 0.05 | 0.1 | ABCA1 expression enhancer | |||
| 0.085 | 0.036 | 0.085 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.077 | 0.029 | 0.077 | Aryl hydrocarbon receptor antagonist | |||
| 0.106 | 0.058 | 0.134 | Gastric antisecretory | 0.134 0.034 DBMET03578 | DBMET03578 | |
| 0.206 | 0.16 | 0.256 | Cholesterol antagonist | 0.256 0.121 DBMET03578 | DBMET03578 | |
| 0.118 | 0.072 | 0.118 | MAP kinase 12 inhibitor | |||
| 0.053 | 0.013 | 0.053 | Purinergic P2X7 antagonist | |||
| 0.147 | 0.107 | 0.147 | ATPase inhibitor | |||
| 0.127 | 0.089 | 0.127 | Death-associated protein kinase 1 inhibitor | |||
| 0.097 | 0.06 | 0.097 | Fibroblast growth factor 1 antagonist | |||
| 0.078 | 0.04 | 0.078 | Prostaglandin-E synthase inhibitor | |||
| 0.158 | 0.123 | 0.158 | MAP kinase kinase 5 inhibitor | |||
| 0.06 | 0.028 | 0.06 | Dihydroorotate dehydrogenase inhibitor | |||
| 0.06 | 0.029 | 0.06 | Melanin-concentrating hormone receptor 1 antagonist | |||
| 0.042 | 0.013 | 0.042 | Glucagon receptor antagonist | |||
| 0.064 | 0.035 | 0.064 | Heme oxygenase stimulant | 0.06 0.046 DBMET03578 | ||
| 0.054 | 0.027 | 0.054 | Sodium/calcium exchanger inhibitor | 0.047 0.043 DBMET03578 | ||
| 0.198 | 0.171 | 0.198 | Caspase 3 stimulant | |||
| 0.094 | 0.068 | 0.094 | MAP kinase 9 inhibitor | |||
| 0.131 | 0.104 | 0.131 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.096 | 0.071 | 0.096 | MAP kinase kinase kinase inhibitor | |||
| 0.093 | 0.07 | 0.093 | Ephrin antagonist | |||
| 0.092 | 0.071 | 0.193 | Chemokine receptor antagonist | 0.193 0.019 DBMET03578 | DBMET03578 | |
| 0.075 | 0.055 | 0.075 | Focal adhesion kinase 1 inhibitor | |||
| 0.092 | 0.072 | 0.092 | Aurora-A kinase inhibitor | |||
| 0.06 | 0.043 | 0.06 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.071 | 0.054 | 0.071 | Histone deacetylase SIRT1 stimulant | |||
| 0.071 | 0.054 | 0.071 | Histone deacetylase stimulant | |||
| 0.044 | 0.028 | 0.066 | CC chemokine 3 receptor antagonist | 0.066 0.017 DBMET03578 | DBMET03578 | |
| 0.073 | 0.058 | 0.073 | Glutamate (mGluR) antagonist | |||
| 0.071 | 0.056 | 0.071 | Rho-associated kinase I inhibitor | |||
| 0.039 | 0.025 | 0.039 | Potassium channel Kv1.1 blocker | |||
| 0.13 | 0.117 | 0.13 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.043 | 0.03 | 0.043 | Liver X receptor agonist | |||
| 0.07 | 0.057 | 0.07 | Rho-associated kinase II inhibitor | |||
| 0.056 | 0.043 | 0.056 | EphB4 antagonist | |||
| 0.148 | 0.136 | 0.148 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.04 | 0.028 | 0.04 | CF transmembrane conductance regulator antagonist | 0.038 0.035 DBMET03578 | ||
| 0.039 | 0.028 | 0.039 | VCAM-1 antagonist | 0.039 0.03 DBMET03578 | ||
| 0.039 | 0.028 | 0.039 | VCAM antagonist | 0.039 0.03 DBMET03578 | ||
| 0.104 | 0.093 | 0.104 | Nav1.3 sodium channel blocker | |||
| 0.094 | 0.084 | 0.094 | Polo-like kinase-4 inhibitor | |||
| 0.245 | 0.235 | 0.245 | 5 Hydroxytryptamine release inhibitor | |||
| 0.208 | 0.199 | 0.208 | Antiobesity | |||
| 0.088 | 0.081 | 0.088 | Insulin receptor antagonist | |||
| 0.123 | 0.117 | 0.123 | Sphingosine 1-phosphate receptor 5 antagonist | |||
| 0.051 | 0.047 | 0.051 | Dihydroorotate oxidase inhibitor | |||
| 0.022 | 0.018 | 0.022 | Epoxide hydrolase 2 inhibitor | |||
| 0.047 | 0.044 | 0.047 | Antiviral (Hepatitis D) | |||
| 0.046 | 0.043 | 0.046 | Diacylglycerol O-acyltransferase inhibitor | |||
| 0.039 | 0.037 | 0.039 | Purinergic P2Y antagonist | |||
| 0.093 | 0.091 | 0.093 | Interleukin 1b antagonist | |||
| 0.022 | 0.02 | 0.022 | ICAM 1 antagonist | |||
| 0.099 | 0.098 | 0.099 | Glutamate receptor antagonist | |||
| 0.028 | 0.027 | 0.028 | Cyclophilin A inhibitor | |||
| 0.022 | 0.03 | 0.031 | Protocollagen prolyl hydroxylase inhibitor | 0.031 0.014 DBMET03578 | DBMET03578 | |
| 0.063 | 0.073 | 0.177 | CC chemokine receptor antagonist | 0.177 0.014 DBMET03578 | DBMET03578 | |
| 0.017 | 0.028 | 0.024 | NMDA receptor glycine site antagonist | 0.024 0.017 DBMET03578 | DBMET03578 | |
| 0.252 | 0.264 | 0.56 | Antiinflammatory | 0.56 0.065 DBMET01001 | DBMET01001 | |
| 0.226 | 0.24 | 0.526 | Cyclophilin D inhibitor | 0.526 0.043 DBMET01001 | DBMET01001 | |
| 0.191 | 0.213 | 0.472 | Toll-Like receptor 7 agonist | 0.472 0.038 DBMET03578 | DBMET03578 | |
| 0.039 | 0.066 | 0.05 | Acetyl-CoA transferase inhibitor | 0.05 0.041 DBMET03578 | DBMET03578 | |
| 0.088 | 0.121 | 0.099 | Cell adhesion inhibitor | 0.099 0.092 DBMET01001 | DBMET01001 | |
| 0.028 | 0.066 | 0.038 | Acetyl-CoA transferase 1 inhibitor | 0.038 0.033 DBMET03578 | DBMET03578 | |
| 0.181 | 0.227 | 0.459 | Toll-Like receptor agonist | 0.459 0.041 DBMET03578 | DBMET03578 | |
| 0.047 | 0.099 | 0.072 | CXC chemokine receptor antagonist | 0.072 0.046 DBMET03578 | DBMET03578 | |
| 0.022 | 0.079 | 0.081 | Chemokine receptor agonist | 0.081 0.008 DBMET03578 | DBMET03578 | |
| 0.009 | 0.069 | 0.045 | CXC chemokine receptor agonist | 0.045 0.008 DBMET03578 | DBMET03578 | |
| 0.066 | 0.137 | 0.129 | Chelator | 0.129 0.046 DBMET03578 | DBMET03578 | |
| 0.11 | 0.187 | 0.127 | CC chemokine 6 receptor antagonist | 0.127 0.083 DBMET01001 | DBMET01001 | |
| 0.027 | 0.122 | 0.153 | Selectin antagonist | 0.153 0.017 DBMET01001 | DBMET01001 | |
| 0.1 | 0.2 | 0.145 | Interleukin 6 antagonist | 0.145 0.096 DBMET03578 | DBMET03578 | |
| 0.03 | 0.133 | 0.052 | Heparanase inhibitor | 0.052 0.039 DBMET01001 | DBMET01001 | |
| 0.136 | 0.262 | 0.167 | Nitric-oxide synthase stimulant | 0.167 0.162 DBMET03578 | DBMET03578 | |
| 0.1 | 0.236 | 0.484 | Tumour necrosis factor alpha release inhibitor | 0.301 0.053 DBMET03578 0.484 0.015 DBMET01001 | DBMET01001 | |
| 0.015 | 0.156 | 0.051 | Factor XIa inhibitor | 0.051 0.018 DBMET03578 | DBMET03578 | |
| 0.082 | 0.251 | 0.154 | Hypolipemic | 0.154 0.133 DBMET01001 | DBMET01001 | |
| 0.025 | 0.194 | 0.055 | Factor IXa inhibitor | 0.05 0.038 DBMET03578 0.055 0.031 DBMET01001 | DBMET01001 | |
| 0.099 | 0.437 | 0.235 | Peptidyltransferase inhibitor | 0.235 0.062 DBMET01001 | DBMET01001 | |
| 0.015 | 0.653 | 0.197 | Angiogenesis stimulant | 0.197 0.096 DBMET01001 | DBMET01001 | |
| 0.009 | 0.649 | 0.091 | Bronchodilator | 0.091 0.074 DBMET03578 | DBMET03578 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |